Biography
Background
I am a statistician with interests in methods for improving the design and analysis of clinical trials. As well as working in methodology development I have a great interest in collaborating on real trials to apply new methods in practice.
I have been at Newcastle University since July 2017.
Areas of expertise
- Biostatistics
- Clinical trials
- Novel trial design
Research
My research focuses on statistical methods for improved design and analysis of clinical trials. I am particularly interested in:
- Adaptive designs for clinical trials;
- Methods for incorporating biomarkers into clinical trials to stratify patients by treatment response;
- Improved methods for analysing composite endpoints, in particular ones with continuous components.
Scopus: Click here
Contact
- Email: james.wason@ncl.ac.uk
- Telephone: +44 (0) 191 208 3699
- Address: Population Health Sciences Institute, 4th Floor Ridley Building 1, Queen Victoria Road, Newcastle upon Tyne NE1 7RU, UK
FAQs
Q: How do you pronounce your surname?
A: It rhymes with Mason, like ‘Way-son’.
Publications
Quickly discover relevant content by filtering publications.
(2022).
Point estimation following a two-stage group sequential trial.
Statistical Methods in Medical Research.
(2022).
Bayesian modelling strategies for borrowing of information in randomised basket trials.
Journal of the Royal Statistical Society: Series C (Applied Statistics).
(2022).
Design and analysis of umbrella trials: Where do we stand?.
Frontiers in Medicine.
(2022).
Subgroup analyses in randomized controlled trials frequently categorized continuous subgroup information.
Journal of Clinical Epidemiology.
(2022).
A hybrid approach to comparing parallel-group and stepped-wedge cluster-randomized trials with a continuous primary outcome when there is uncertainty in the intra-cluster correlation.
Clinical Trials.
(2022).
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls.
Gastroenterology.
(2022).
Bayesian sample size determination in basket trials borrowing information between subsets.
Biostatistics.
(2022).
Practical guidance for planning resources required to support publicly-funded adaptive clinical trials.
BMC Medicine.
(2022).
Imaging Glioblastoma Metabolism by Using Hyperpolarized [1-$łess$sup$greater$13$łess$/sup$greater$C]Pyruvate Demonstrates Heterogeneity in Lactate Labeling: A Proof of Principle Study.
Radiology: Imaging Cancer.
(2022).
Adaptive Designs: Benefits and Cautions for Neurosurgery Trials.
World Neurosurgery.
(2022).
Components of smartphone cognitive-behavioural therapy for subthreshold depression among 1093 university students: a factorial trial.
Evidence Based Mental Health.
(2022).
Effects of Exercise and Sleep Deprivation on Reaction Severity During Oral Peanut Challenge: A Randomized Controlled Trial.
The Journal of Allergy and Clinical Immunology: In Practice.
(2022).
When is a two-stage single-arm trial efficient? An evaluation of the impact of outcome delay.
European Journal of Cancer.
(2022).
Bayesian sample size determination using commensurate priors to leverage preexperimental data.
Biometrics.
(2022).
Capturing the real-world benefit of residual $p̆beta$-cell function during clinically important time-periods in established Type 1 diabetes.
Diabetic Medicine.
(2022).
Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis.
Neurology.
(2022).
The role of comorbidities alongside patient and disease characteristics on long-term disease activity in RA using UK inception cohort data.
Rheumatology.
(2022).
Response adaptive intervention allocation in stepped-wedge cluster randomized trials.
Statistics in Medicine.
(2022).
Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials.
BMC Cancer.
(2022).
Determining the OPTIMAL DTI analysis method for application in cerebral small vessel disease.
NeuroImage: Clinical.